Literature DB >> 8443922

Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis. Implications for clinical trials.

D Waters1, J Lespérance, T E Craven, G Hudon, L D Gillam.   

Abstract

BACKGROUND: Clinical trials with angiographic end points have been used to assess whether interventions influence the evolution of coronary atherosclerosis because sample size requirements are much smaller than for trials with hard clinical end points. Further studies of the variability of the computer-assisted quantitative measurement techniques used in such studies would be useful to establish better standardized criteria for defining significant change. METHODS AND
RESULTS: In 21 patients who had two arteriograms 3-189 days apart, we assessed the reproducibility of repeat quantitative measurements of 54 target lesions under four conditions: 1) same film, same frame; 2) same film, different frame; 3) same view from films obtained within 1 month; and 4) same view from films 1-6 months apart. Quantitative measurements of 2,544 stenoses were also compared with an experienced radiologist's interpretation. The standard deviation of repeat measurements of minimum diameter from the same frame was very low (0.088 mm) but increased to 0.141 mm for measurements from different frames. It did not increase further for films within 1 month but increased to 0.197 mm for films 1-6 months apart. Diameter stenosis measurements were somewhat more variable. Measurement variability for minimum diameter was independent of vessel size and stenosis severity. Experienced radiologists did not systematically overestimate or underestimate lesion severity except for mild overestimation (mean 3.3%) for stenoses > or = 70%. However, the variability between visual and quantitative measurements was two to three times higher than the variability of paired quantitative measurements from the same frame.
CONCLUSIONS: Changes of 0.4 mm or more for minimum diameter and 15% or more for stenosis diameter (e.g., 30-45%), measured quantitatively, are recommended as criteria to define progression and regression. Approaches to data analysis for coronary arteriographic trials are discussed.

Entities:  

Mesh:

Year:  1993        PMID: 8443922

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Noninvasive prediction of coronary artery disease progression by comparison of serial exercise electrocardiography and dipyridamole stress echocardiography.

Authors:  Olaf Rodriguez; Eugenio Picano; Silvio Fedele; Martha Morelos; Mario Marzilli
Journal:  Int J Cardiovasc Imaging       Date:  2002-04       Impact factor: 2.357

2.  Measuring progression and regression of coronary atherosclerosis in clinical trials: problems and progress.

Authors:  J Lespérance; D Waters
Journal:  Int J Card Imaging       Date:  1992

3.  Validation of coronary artery saphenous vein bypass graft diameter measurements using quantitative angiography.

Authors:  J Lespérance; L Campeau; J H Reiber; M Bois; I Dyrda; J Laurier; G Hudon
Journal:  Int J Card Imaging       Date:  1996-12

4.  Diagnostic accuracy of 320-row computed tomography as compared with invasive coronary angiography in unselected, consecutive patients with suspected coronary artery disease.

Authors:  F Pelliccia; V Pasceri; A Evangelista; A Pergolini; F Barillà; N Viceconte; G Tanzilli; M Schiariti; C Greco; C Gaudio
Journal:  Int J Cardiovasc Imaging       Date:  2012-07-18       Impact factor: 2.357

5.  Effect of exercise-based cardiac rehabilitation on non-culprit mild coronary plaques in the culprit coronary artery of patients with acute coronary syndrome.

Authors:  Satoshi Kurose; Junji Iwasaka; Hiromi Tsutsumi; Yutaka Yamanaka; Hiromi Shinno; Yaeko Fukushima; Kyoko Higurashi; Masaru Imai; Izuru Masuda; Shinichi Takeda; Chuichi Kawai; Yutaka Kimura
Journal:  Heart Vessels       Date:  2015-04-21       Impact factor: 2.037

Review 6.  [Assessment of progression and regression of coronary atherosclerosis by coronary angiography].

Authors:  Raimund Erbel
Journal:  Herz       Date:  2015-09       Impact factor: 1.443

7.  Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients.

Authors:  Li Jin Pu; Lin Lu; Rui Yan Zhang; Run Du; Ying Shen; Qi Zhang; Zheng Kun Yang; Qiu Jing Chen; Wei Feng Shen
Journal:  Diabetes Care       Date:  2012-12-10       Impact factor: 19.112

8.  A novel ultrafast-low-dose computed tomography protocol allows concomitant coronary artery evaluation and lung cancer screening.

Authors:  Carlo Gaudio; Gennaro Petriello; Francesco Pelliccia; Alessandra Tanzilli; Alberto Bandiera; Gaetano Tanzilli; Francesco Barillà; Vincenzo Paravati; Massimo Pellegrini; Enrico Mangieri; Paolo Barillari
Journal:  BMC Cardiovasc Disord       Date:  2018-05-08       Impact factor: 2.298

9.  Concomitant screening of coronary artery disease and lung cancer with a new ultrafast-low-dose Computed Tomography protocol: A pilot randomised trial.

Authors:  Carlo Gaudio; Alessandra Tanzilli; Mariachiara Mei; Andrea Moretti; Francesco Barillà; Antonio Varveri; Vincenzo Paravati; Gaetano Tanzilli; Antonio Ciccaglioni; Stefano Strano; Massimo Pellegrini; Paolo Barillari; Francesco Pelliccia
Journal:  Sci Rep       Date:  2019-09-25       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.